Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Chief Legal Officer | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viridian Therapeutics, Inc.\DE
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-19 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-19 · Sale · Disposed 4,212 · Balance 0 F1: The shares sold include 718 shares previously acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c). Row 2 · 2026-08-19 · Exercise / conversion · Acquired 10,000 · Balance 10,000 Row 3 · 2026-08-19 · Sale · Disposed 10,000 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.41 · Expires 2035-03-03 | Direct | 114,072 |
Reported balance
After 2026-08-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-19 · Exercise / conversion · Disposed 10,000 · Balance 114,072 F2: The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares sold include 718 shares previously acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c).
F2: The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 21, 2026 00:05 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $14.41 | $0.00 |
DisclosureSEC source: 0001193125-26-359636 · ownership.xml · derivative · entry 4 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,072 Underlying: Common Stock · 10,000 shares Expires 2035-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 00:05 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 10,000 | $24.50 | $245,000.00 |
DisclosureSEC source: 0001193125-26-359636 · ownership.xml · nonDerivative · entry 3 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 00:05 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 10,000 | $14.41 | $144,100.00 |
DisclosureSEC source: 0001193125-26-359636 · ownership.xml · nonDerivative · entry 2 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 00:05 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 4,212 | $24.50 | $103,194.00 |
DisclosureSEC source: 0001193125-26-359636 · ownership.xml · nonDerivative · entry 1 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The shares sold include 718 shares previously acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c). Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 00:17 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionRestricted Stock Units · Derivative | 5,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-092074 · ownership.xml · derivative · entry 5 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,510 Underlying: Common Stock · 5,169 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date. F4 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 00:17 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Tax withholdingCommon Stock | 1,724 | $29.32 | $50,547.68 |
DisclosureSEC source: 0001193125-26-092074 · ownership.xml · nonDerivative · entry 2 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,445 Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 00:17 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 5,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-092074 · ownership.xml · nonDerivative · entry 1 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| March 03, 2026 Filed Mar 9, 2026 23:35 UTC Amendment | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Tax withholdingCommon Stock | 1,675 | $30.19 | $50,568.25 |
DisclosureSEC source: 0001193125-26-099008 · ownership.xml · nonDerivative · entry 1 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,494 F1 · shares: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4. F1 · balance_after: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:17 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantRestricted Stock Units · Derivative | 23,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-092074 · ownership.xml · derivative · entry 4 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,850 Underlying: Common Stock · 23,850 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:17 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 119,300 | $0.00 Strike: $30.25 | $0.00 |
DisclosureSEC source: 0001193125-26-092074 · ownership.xml · derivative · entry 3 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,300 Underlying: Common Stock · 119,300 shares Expires 2036-03-02 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 22:25 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 2,272 | $31.16 | $70,795.52 |
DisclosureSEC source: 0001193125-26-001097 · ownership.xml · nonDerivative · entry 1 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Consists of shares purchased under the Issuer's employee stock purchase plan. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 02:17 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantRestricted Stock Units · Derivative | 20,679 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032908 · ownership.xml · derivative · entry 2 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,679 Underlying: Common Stock · 20,679 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 02:17 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 124,072 | $0.00 Strike: $14.41 | $0.00 |
DisclosureSEC source: 0000950170-25-032908 · ownership.xml · derivative · entry 1 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,072 Underlying: Common Stock · 124,072 shares Expires 2035-03-03 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 3, 2025. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:05 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 290,000 | $0.00 Strike: $19.68 | $0.00 |
DisclosureSEC source: 0000950170-24-015205 · ownership.xml · derivative · entry 1 Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2034-02-12 F1 · derivative.exercise_date: The option vests as to 25% on February 12, 2025 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.